1-2 of 2
Mohammad Azab
Close
Sort by
Journal Articles

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Clinical Trials & Observations
Gail J. Roboz, Guillermo Sanz, Elizabeth A. Griffiths, Karen Yee, Hagop Kantarjian, Christian Récher, Michael T. Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L. O'Connell, Yong Hao, Harold N. Keer, Mohammad Azab, Hartmut Döhner
Journal: Blood Advances
Blood Adv (2024) 8 (8): 2020–2029.
https://doi.org/10.1182/bloodadvances.2023012062
Published: 2024
Includes: Supplemental data
Journal Articles

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Clinical Trials & Observations
Pierre Fenaux, Marco Gobbi, Patricia L. Kropf, Jean-Pierre J. Issa, Gail J. Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw. W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph Brandwein, Liana Gercheva-Kyuchukova, Judit Demeter, Elizabeth Griffiths, Karen Yee, Konstanze Döhner, Yong Hao, Harold Keer, Mohammad Azab, Hartmut Döhner
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5027–5037.
https://doi.org/10.1182/bloodadvances.2023010179
Published: 2023
Includes: Supplemental data